Trump BYPASSES FDA — Risky Drug Rushed to Veterans?

FDA warning stamp near stethoscope and keyboard — FDA BYPASSED

President Trump signs an executive order fast-tracking risky psychedelic ibogaine for veterans’ PTSD, raising alarms over safety amid a desperate push to cut through federal red tape.

Story Highlights

Trump allocates $50 million to match state funding for psychedelic research targeting PTSD, addiction, and mental illness in veterans.
The order directs the FDA and the DEA to enable Right to Try access for drugs like ibogaine despite its Schedule I status and cardiac risks.
Ibogaine, linked to 27 deaths and heart arrhythmias, gets explicit mention amid calls for faster reviews.
Texas leads state efforts with federal backing, building on Trump’s 2018 Right to Try precedent.

Executive Order Details

On April 18, 2026, President Donald Trump signed an executive order accelerating federal research and access to psychedelic drugs for serious mental illness. The directive allocates $50 million through ARPA-H to match state investments in treatments for PTSD, traumatic brain injuries, addiction, depression, and related conditions, especially among veterans.

It directs HHS, FDA, and DEA to create Right to Try pathways for eligible patients while prioritizing FDA reviews. Ibogaine remains a Schedule I substance with no immediate rescheduling.

Focus on Controversial Ibogaine

Ibogaine, derived from the African Tabernanthe iboga shrub, has been used traditionally in Bwiti rituals and has drawn modern interest since the 1960s for interrupting addiction.

A 2023 Stanford study of 24 trials involving 705 participants showed promise in reducing withdrawal and cravings but highlighted cardiac toxicity, including QT prolongation, arrhythmias, and 27 reported deaths. Americans currently seek treatment at unregulated clinics in Mexico and the Caribbean due to the U.S. ban since 1970.

NIDA Director Nora Volkow emphasized heart risks in 2024. Despite lacking Phase I trials, the order names ibogaine twice, prompting expert surprise from Harvard’s Glenn Cohen and Mason Marks, who note overlooked state church uses and Texas’s 2025 research consortium.

Trump signs order to speed review of psychedelics, including the controversial drug ibogainehttps://t.co/1ndcZ6JYjv pic.twitter.com/QRget6qwpP

— 1010 WINS on 92.3 FM (@1010WINS) April 18, 2026

Stakeholders and Veteran Advocacy

Veterans and advocates drive the push, facing PTSD and TBI amid a mental health crisis affecting over 14 million Americans. Trump administration officials, including HHS and FDA, implement funding and pathways. Texas government pioneers ibogaine trials, now eligible for federal matching.

Critics, including doctors, argue the move prioritizes politics over science, warning of unproven hype risking lives without rigorous protocols like Stanford’s magnesium monitoring.

Power dynamics pit executive action against regulatory caution, with FDA balancing evidence and innovation. Trump’s order echoes his 2018 Right to Try Act for terminal patients and contrasts with advanced psychedelics like MDMA and psilocybin holding FDA Breakthrough designations.

Impacts and Broader Concerns

Short-term, the order boosts trials and aids desperate patients via Right to Try, potentially normalizing psychedelics over opioids and SSRIs. Long-term, successful Phase I trials could lead to approvals, filling treatment gaps but intensifying safety scrutiny. Economically, $50 million spurs industry growth through state-federal synergy.

Politically, it advances Trump’s veteran support amid Democrat obstruction, yet fuels shared bipartisan frustration with federal failures blocking American innovation and self-reliance. This development underscores elite bureaucratic hurdles thwarting solutions for everyday Americans pursuing health through determination.